The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.
Two new studies published in JAMA Neurology reveal that GLP-1 receptor agonists, like Ozempic and Trulicity, may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback